Clicky

Health

Halberd’s COVID-19 Antibody is the Only One In Competitive Tests to Bind to Omicron Variant
146 37 Merci

JACKSON CENTER, PA / ACCESSWIRE / March 1, 2022 / Halberd Corporation’s (OTC PINK:HALB) previously developed SARS-CoV-2 antibody demonstrated superior binding capability to the SARS-CoV-2 Omicron variant disease antigen. The Halberd antibody was tested against…

  • Merci
  • 0
  • 0

Moderna Initiates Phase 3 Portion of Pivotal Trial for mRNA Respiratory Syncytial Virus (RSV) Vaccine Candidate, Following Independent Safety Review of Interim Data
1200 277 Merci

Endorsement to proceed given by the independent Data and Safety Monitoring Board based on preliminary Phase 2 safety and tolerability data Moderna expects to enroll approximately 34,000 participants in multiple countries RSV causes severe disease…

  • Merci
  • 0
  • 0

Moderna Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Updates
1200 277 Todd

Q4 2021 revenues of $7.2 billion; GAAP net-income of $4.9 billion and GAAP diluted EPS of $11.29 Full year 2021 revenues of $18.5 billion; GAAP net-income of $12.2 billion and GAAP diluted EPS of $28.29…

  • Todd
  • 0
  • 0

Therapeutic Goods Administration of Australia Authorizes Moderna’s Covid-19 Vaccine in Children (6-11 Years)
1200 277 Todd

CAMBRIDGE, MA / ACCESSWIRE / February 16, 2022 / Moderna, Inc., (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Therapeutic Goods Administration (TGA) in Australia has granted provisional…

  • Todd
  • 0
  • 0

CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK
933 574 Jane

– Multivalent technology approach for seasonal influenza mRNA vaccine candidate addressing four different influenza strains – Influenza candidate developed in collaboration with GSK within broad infectious disease vaccine program TÜBINGEN, GERMANY and BOSTON, MA /…

  • Jane
  • 0
  • 0

Empower Clinics Signs Partnership with One of North America’s Largest Terminal Operators to Provide COVID Testing Services
600 600 Todd

Partnership with CERES Terminals Canada Supporting the safe return of the cruise ship industry to Vancouver with more than 1,200,000 passengers anticipated for 2022 VANCOUVER, BC / ACCESSWIRE / February 10, 2022 / EMPOWER CLINICS…

  • Todd
  • 0
  • 0

Panacea Announces Launch of New Product COVID CBDA(TM)
1500 600 Todd

“Orally bioavailable and with a long history of safe human use, these cannabinoids, isolated or in hemp extracts, have the potential to prevent as well as treat infection by SARS-CoV-2” the researchers stated in the…

  • Todd
  • 0
  • 0

Relief Reports US Collaboration Partner Announces Expansion of Aviptadil US Expanded Access & Right to Try Programs for Patients w/COVID-19 Respiratory Failure who’ve Exhausted All Approved Therapies
440 386 Merci

GENEVA, SWITZERLAND / ACCESSWIRE / January 19, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (“Relief“), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the…

  • Merci
  • 0
  • 0

Eyam Vaccines and Immunotherapeutics Welcomes New Board Members and Scientific Advisors
594 280 admin

VANCOUVER, BC / ACCESSWIRE / January 10, 2022 / Eyam Vaccines and Immunotherapeutics is pleased to publicly announce the appointment of Elizabeth Varki Jobes and Dr. Terry Pearson to the Board of Directors, and the…